DGAP-News: MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys’s Novel Immuno-Oncology Agent MOR210

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys’s Novel Immuno-Oncology Agent MOR210 (news with additional features) 15.11.2018 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, November 15, 2018   MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys’s Novel Immuno-Oncology Agent MOR210   MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma (“I-Mab”), a biotech company focusing exclusively on innovative biologics in immuno-oncology and autoimmune diseases, jointly announced today that they have entered into an exclusive strategic collaboration and ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 7

Ähnlich Nachrichten